Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Hypertrophic cardiomyopathy (HCM) is a prevalent heart muscle disorder affecting millions worldwide.
• Disease course is influenced by genetics, age, gender, comorbidities, and environmental factors.
• Diagnostic approaches have evolved from echocardiography to multimodal strategies including advanced imaging, genetics, and biomarkers.

Purpose of the Study:

• To review Mavacamten, a selective allosteric cardiac myosin inhibitor.
• To discuss its mechanism of action in treating hypertrophic cardiomyopathy (HCM).
• To evaluate its potential impact on patient outcomes and current treatment paradigms.

Main Methods:

• Review of existing literature on Mavacamten and hypertrophic cardiomyopathy.
• Analysis of Mavacamten's pharmacological action on cardiac myosin and actomyosin interactions.
• Examination of clinical trial data regarding Mavacamten's efficacy and safety.

Main Results:

• Mavacamten reduces pathological actomyosin interactions in HCM, decreasing cross-bridge formation.
• This mechanism normalizes left ventricular outflow tract pressure and improves cardiac filling.
• Clinical studies demonstrate significant improvements in exercise capacity and symptom relief, reducing the need for invasive procedures.

Conclusions:

• Mavacamten represents a potential transformative pharmacological treatment for obstructive hypertrophic cardiomyopathy.
• It effectively alleviates symptoms like chest pain and dyspnea.
• Further research is warranted to confirm long-term clinical benefits and solidify its role in HCM management.